Valproic Acid - Therapeutic use
Research News and Information

Monday, November 23, 2009

An initial report of a new biological marker for bipolar disorder: P85 evoked brain potential.

30 Aug 2009 OBJECTIVES: Progress toward understanding the neurobiological and genetic underpinnings of bipolar disorder has been limited by the scarcity of potential biological markers that predict its occurrence. A measure of the integrity of brain inhibitory ... Read more...

Rational polytherapy.

30 Aug 2009 Monotherapy has been considered the gold standard for drug treatment of epilepsy. However, there is renewed interest in polytherapy because of the advent of new drugs with fewer drug interactions and novel mechanisms of action, and the realization ... Read more...

Use of a new antiepileptic drug or an old one as first drug for treatment of absence epilepsy.

30 Aug 2009 Treatment of absence epilepsy requires understanding the efficacy and side effects of several drugs, one of which first became available more than 50 years ago. Methods for drug development and procedures for evaluating their safety and efficacy ... Read more...

Latest indexed articles for 'Valproic Acid - Therapeutic use'

These are the very latest articles for this heading:

• Combination treatment with quetiapine in bipolar disorder patients. 29 Sep 2009
• Chitosan may decrease serum valproate and increase the risk of seizure reappearance. 22 Sep 2009
• An initial report of a new biological marker for bipolar disorder: P85 evoked brain potential. 30 Aug 2009
• Rational polytherapy. 30 Aug 2009
• Use of a new antiepileptic drug or an old one as first drug for treatment of absence epilepsy. 30 Aug 2009
• The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? 30 Aug 2009
• Pregnancy treatment guidelines: throwing the baby out with the bath water. 30 Aug 2009
• Unilateral eyelid angiofibroma with complete blepharoptosis as the presenting sign of tuberous sclerosis. 30 Jul 2009
• Divalproex is not effective for children with bipolar disorder. 30 Jul 2009
• Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. 30 Jul 2009
• Poor applicability of estimation method for adults to calculate unbound serum concentrations of valproic acid in epileptic neonates and infants. 30 Jul 2009
• Divalproex sodium in children with partial seizures: 12-month safety study. 30 Jul 2009
• Rational treatment options with AEDs and ketogenic diet in Landau-Kleffner syndrome: still waiting after all these years. 30 Jul 2009
• Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model. 8 Jul 2009
• Traditional Chinese medicine for epilepsy. 6 Jul 2009
• Valproate preparations for agitation in dementia. 6 Jul 2009
• LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. 5 Jul 2009
• Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study. 5 Jul 2009
• Ring chromosome 20 syndrome: a link between epilepsy onset and neuropsychological impairment in three children. 30 Jun 2009
• [Inadequate vasopressin secretion and valproate] 29 Jun 2009

See a longer list of these articles.

Technical information about 'Valproic Acid'

Definition: A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of voltage dependent sodium channels.

Chemical name: Pentanoic acid, 2-propyl-

Registry Number: 99-66-1

Descriptor UI: D014635

Alternative terms: Valproic Acid; Acid, Valproic; 2-Propylpentanoic Acid; 2 Propylpentanoic Acid; Divalproex; Convulsofin; Depakene; Depakine; Depakote; Vupral; Divalproex Sodium; Sodium, Divalproex; Semisodium Valproate; Valproate, Semisodium; Valproic Acid, Sodium Salt (2:1); Ergenyl; Magnesium Valproate; Valproate, Magnesium; Sodium Valproate; Valproate, Sodium; Valproate Sodium; Sodium, Valproate; Valproate; Calcium Valproate; Valproate, Calcium; Dipropyl Acetate; Acetate, Dipropyl;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antimanic Agents; Anticonvulsants; Enzyme Inhibitors; GABA Agents;

Tree Number: D02.241.081.944.509.900; D10.251.400.895.593.900;

Online Note: use VALPROIC ACID to search VALPROATE 1979-90 & DIPROPYL ACETATE 1975-90

History Note: 91; was VALPROATE 1979-90; was DIPROPYL ACETATE see under VALERATES 1975-78